Navigation Links
Patients at Risk for Hepatitis B Are Not Adequately Screened Before Receiving Chemotherapy Leading to the Preventable Reactivation of Hepatitis B Infection
Date:11/7/2011

SAN FRANCISCO, Nov. 7, 2011 /PRNewswire/ -- By examining 70,737 patients through institutional databases and medical charts, researchers at The University of Texas MD Anderson Cancer Center determined that only 20 percent of patients with newly diagnosed cancer who had hepatitis B virus (HBV) risk factors were screened for HBV infection before starting chemotherapy. This amount of screening is inadequate, according to Jessica P. Hwang, MD, MPH, the lead author of the study, "I hope my study results will increase awareness among medical providers so that they will actively screen for hepatitis B viral infection to prevent poor outcomes for these patients after their chemotherapy."

For patients with HBV infection, the danger is that their hepatitis B virus can be reactivated by chemotherapy. While those with reactivated HBV infection can be treated with antiviral therapy, initiating antiviral prophylaxis prior to chemotherapy can prevent reactivation. Using well-known HBV risk factors, a greater percentage of cancer patients with HBV infection can be accurately identified and successfully treated before starting chemotherapy.

Unfortunately, reactivation is common and may have occurred in nearly 25 percent of all patients with HBV who were newly diagnosed with cancer and received chemotherapy. This reactivation of HBV infection is preventable with screening and antiviral prophylaxis prior to the onset of chemotherapy. The study's conclusion clearly states that screening and prophylactic treatment of HBV infection prior to chemotherapy could reduce mortality in cancer patients with HBV.

"Reactivation is preventable and depends only on accurate screening and prophylaxis. For medical providers to practice effective screening, data-driven policies and strong collaboration among oncology and hepatology communities are essential," concludes Dr. Wang.

Abstract title:

Reactivation of Hepatitis B Infection Among Patients with Cancer

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in San Francisco, California, November 4 – 8, will bring together more than 8,000 researchers from 55 countries.

A press room will be available from November 5 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766.

Press releases and all abstracts are available online at www.aasld.org.

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


'/>"/>
SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Health of Patients with Nonalcoholic Steatohepatitis Improved Through Treatment with Anti-CD3 Antibodies
2. New Data on Patient-Reported Improvements in Quality of Life Measures and Other Clinical Responses in Moderate to Severe Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol) Highlighted at American College of Rheumatology Meeting
3. New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
4. Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease
5. Innovative Access Device Provides Hope for Select Hemodialysis Patients
6. Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
7. Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients
8. Hong Kong Cancer Center First in Asia to Commence Treating Cancer Patients Using TrueBeam™ System for Image-Guided Radiotherapy
9. Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors
10. UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting
11. Groundbreaking Approach to Predicting Cancer Patients Response to Treatment Featured in Science Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 Amarantus BioScience ... on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today ... be presenting at two upcoming investor conferences: SeeThru ... Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
Breaking Medicine Technology:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... With over ... to walk, the demand for a sustainable product to aid in the rehabilitation process ... aid in the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. ... from leading advocates, associations and industry leaders such as Bioness. , As ...
(Date:5/27/2016)... ... , ... Beleza Medspa has initiated a new program to assist ... first time that Coolsculpting is being used for for more than just cosmetic purposes. ... meet the prescribed body-fat standard, measured by the circumference-based tape method. The tape-test ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
Breaking Medicine News(10 mins):